Industry S SecureBio
Kimi K3 Biology Capabilities Assessment
The strongest open-weights biology model we've tested is roughly eight months behind the closed frontier, and refuses just over a quarter of hazardous prompts.
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry S SecureBio
The strongest open-weights biology model we've tested is roughly eight months behind the closed frontier, and refuses just over a quarter of hazardous prompts.
Industry P Patent Docs
By Kevin E. Noonan – One of the beneficial characteristics of the response to the COVID-19 pandemic were pledges from companies involved in developing vaccines (such as Moderna, Pfizer, BioNTech, and others) not to enforce patents on relevant technology during the duration. …
Industry P Patent Docs
By Kevin E. Noonan – Arbutus Biopharma and Genevant Sciences, having prevailed in district court litigation against Moderna involving infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 regarding lipid nanoparticle (LNP) technolo…
Industry I In the Pipeline
Most people probably don’t realize it, but the prediction/betting market like Kalshi and Polymarket have begun taking bets on things like the success of Phase III drug trials. The New York Times highlighted this recently, and I wanted to weigh in on this idea. Not least because i…
Industry I In the Pipeline
I’ve remarked before that one of the big differences in the modern chemical literature versus the “back when I was in grad school” era (which for me is the 1980s, dang it all) is that we now can do a lot more at smaller scales. Detailed pictures of surface and single-molecule phe…
Industry
C&EN Pharmaceuticals
Industry W What do you mean heterogeneity?
I was thinking about my reading habits.
Industry I In the Pipeline
If you haven’t read this story yet, you should. It’s an excellent piece of journalism from the team here at Science and at Retraction Watch, and it reveals a previously unreported death from an attempt at gene therapy in China last year. We know where it happened (Xinhua Hospital…
Industry P Practical Fragments
Back in 2009 we highlighted a paper, “Escape from flatland,” suggesting that molecules with higher fractions of sp3-hybridized (ie, non-aromatic) carbons are more likely to become drugs. This hypothesis has been challenged on methodological grounds, and an analysis last year conc…
Industry I In the Pipeline
Here’s some work that ties in with that post I did the other day about bacterial associations with cancer (or the general lack of same). It’s been known for some time that cancer immunotherapy responses are influenced by the human microbiome - for example, antibiotic treatment se…
Industry
Pharmaceutical Processing World
by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list. Overpressure or vacuum…
Industry
C&EN Pharmaceuticals
A recent tragedy in China reminds us of important lessons for managing drug trials of gene therapies
Industry I In the Pipeline
Let’s do some good ol’ organic synthesis today. Probably not so many of the chemists in the audience will have run the good ol’ Appel reaction (alcohol to alkyl chloride with triphenylphosphine and carbon tetrachloride), because good ol’ carbon tet has been disappearing from the…
Industry
C&EN Pharmaceuticals
A biocatalytic platform could offer a scalable strategy for tailoring natural products
Industry I In the Pipeline
There have been a great number of reports over the years of associations between various bacterial species and human tumor tissue, but the problem is that no one has been sure how many of these associations are real. I last wrote about this in 2023 when a big controversy flared u…
Industry
C&EN Pharmaceuticals
Amid long blackouts and dwindling supplies, research and development have become ‘very difficult’
Industry I In the Pipeline
Here’s another one for the “no one ever realized this drug was also doing this” file. And let me tell you, it’s a big file. We develop drugs (for the most part) towards specific biochemical targets, and we assay them against panels of related targets and against common receptors…
Industry S SecureBio
We share our external review of the chemical and biological section of Anthropic's February 2026 Risk Report after months of followup and hundreds of pages reviewed.
Industry
C&EN Pharmaceuticals
A mild, modular approach to adding bicyclobutanes could bring more selectivity to these therapies
Industry I In the Pipeline
There are people who will tell you that a cell is just the way that ribosomes make more ribosomes, and I’m not in a position to say that they’re wrong. It’s for sure that these protein-synthesizing factories are extremely ancient, extremely well-optimized, and they’re constantly…
Industry
Pharmaceutical Processing World
Consider a common scenario: a pharmaceutical manufacturing plant has identified the equipment most critical to the success of its processes and has begun tracking overall equipment effectiveness (OEE) for those assets. Management has set an ambitious OEE metric of 95% for those c…
Industry P Practical Fragments
Earlier this year we highlighted a study that compared the affinities of kinase inhibitors for isolated proteins vs those same proteins in cells and found differences – sometimes dramatic. A new open-access paper in J. Am. Chem. Soc. by Blake Peterson and colleagues at Ohio State…
Industry I In the Pipeline
Now this is some futuristic medicine, I have to say (commentary here at Cell). The authors are looking at “dry eye disease” (keratoconjunctivitis sicca), which can have a rather complex biological background. There are quite a few contributing causes (contact lens use, aging, clo…
Industry I In the Pipeline
I’m fond of saying that the most important single statistic about the drug industry is the clinical failure rate, which is (by any reasonable standard) appallingly high. To my mind, everything that is infuriating or inexplicable to outside observers (or patients!) about the bioph…
Industry S SecureBio
We report findings from our comprehensive pre-deployment assessment of biological and biosecurity-relevant capabilities of GPT-5.6 Sol.
Industry
C&EN Pharmaceuticals
New methods offer simpler routes to diabetes drugs and other carbohydrate-derived medicines
Industry P Patent Docs
By Donald Zuhn – In a Patent Alert distributed last week, the U.S. Patent and Trademark Office reminded stakeholders that beginning on Monday, July 20, patent applicants and owners who are not domiciled in the U.S. or its territories are now required to be represented by a USPTO-…
Industry E EUCOPE
EUCOPE regularly spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In July, we spoke with Stephanie Manton, CEO & Co-founder of WinQure Medicine. Stephanie Manton is the CEO &…
Industry P Patent Docs
By Kevin E. Noonan – Since the institution of inter parte review (IPR) proceedings under the Leahy-Smith America Invents Act in 2012, parallel proceedings before the Patent Trial and Appeals Board and district courts have become somewhat commonplace. Frequently, the former…
Industry I In the Pipeline
I’ve been meaning to write about this post, provocatively entitled “Biotech is Entering Its Netflix Era”. I find a lot to agree with in it, but I have what I think are some fundamental disagreements as well. The author, Matt Shlosberg, believes that the coming wave of AI-accelera…
Industry C Cell Systems
A computational method identifies subcellular signaling microdomains from live-cell movies. The detected microdomains reveal distinct spatiotemporal organization in the signaling of canonical Rho GTPases and GEFs and are sensitive to optogenetic perturbation.
Industry C Cell Systems
Wang et al. show that oscillatory phase-separated condensates enhance TTFL clock robustness by separating translation enhancement from transcriptional repression. Modeling and knockdown experiments support a hybrid architecture in which condensates retain intrinsic rhythmicity wh…
Industry
C&EN Pharmaceuticals
Here’s what we’re watching in the chemical and pharmaceutical industries this week
Industry G GCBR Organization Updates
Updates from CLTR, Coefficient Giving, Global Health Security Network, Mirror Biology Dialogues Fund, CSR, and Blueprint Biosecurity
Industry T The Labs Report
Following our deep dive on lipid nanoparticle (LNP) delivery, Justine Levin-Allerhand sits down with Head of Platform at Mirai Bio, Jagesh Shah for the story behind the data — from why delivery has remained such a persistent challenge to how machine learning,
Industry
C&EN Pharmaceuticals
By undoing lysine glycation, Revel Pharmaceuticals hopes to address tissue stiffness, inflammation
Industry P Practical Fragments
Differential scanning fluorimetry (DSF), also known as a thermal shift assay, is one of the most common techniques for fragment screening according to the most recent methods poll on Practical Fragments. This popularity is in part due to the simplicity of the assay: just mix your…
Industry I In the Pipeline
Let’s talk about pancreatic cancer vaccines, because there are some really interesting long-running projects in that area. I’ve written several times about a therapeutic vaccine for pancreatic ductal adenocarcinomas (the most common type) being developed by Roche and BioNTech, mo…
Industry
LifeSciVC
By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Before attending my first board meeting, I fondly remember imagining a board as the “Room Where It Happens,” yearningly described by Aaron The post The Plus-1 in “The Room Wher…
Industry S SecureBio
Well-calibrated AI safeguards must strike a Goldilocks balance: refusing the dangerous without blocking the benign. BioTIER measures how close models get.